IP Library Granted Patent US 12,084,681
Granted Patent B2
US 12,084,681 · App. 16/575,518 · Granted Sep 10, 2024

Ex vivo antibody production

Inventors: Paula Maria Wilhelmina Van Helden (Amsterdam Zuidoost, NL); Mark Jeroen Kwakkenbos (Amsterdam Zuidoost, NL); Hergen Spits (Amsterdam Zuidoost, NL); Tim Beaumont (Amsterdam Zuidoost, NL)
Assignee: KLING BIOTHERAPEUTICS B.V.
C12N5/0635C07K16/00C07K16/1018C12N15/86C12P21/005C07K2317/14C12N2510/00C12N2510/02C12N2510/04C12N2740/13045C12N2810/6054
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,084,681
App. No.
16/575,518
Granted
Sep 10, 2024
Kind
B2
Abstract

The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.

Claims (45)

1. A method for obtaining antibodies comprising:

inducing, enhancing and/or maintaining expression of Bcl-6, or a rabbit homologue thereof, in a rabbit B cell;

inducing, enhancing and/or maintaining expression of at least one anti-apoptotic nucleic acid molecule in said B cell,

culturing said B cell ex vivo to produce antibodies in a culture medium; and

harvesting antibodies from the culture medium in an amount of at least 100 ng/ml culture medium within 10-14 days from the start of the culturing.

2. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding Bcl- 6 or a functional part or a functional derivative thereof, and/or

at least one anti-apoptotic nucleic acid molecule.

3. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a non-rabbit Bcl-6 or a functional part or a functional derivative thereof, and/or

at least one non-rabbit anti-apoptotic nucleic acid molecule.

4. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a rabbit Bcl-6 or a functional part or a functional derivative thereof, and/or

at least one rabbit anti-apoptotic nucleic acid molecule.

5. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a non-rabbit Bcl-6 or a functional part or a functional derivative thereof, and

at least one non-rabbit anti-apoptotic nucleic acid molecule.

6. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a human or murine Bcl-6 or a functional part or a functional derivative thereof, and/or

at least one human or murine anti-apoptotic nucleic acid molecule.

7. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a human Bcl-6 or a functional part or a functional derivative thereof, and

at least one human anti-apoptotic nucleic acid molecule.

8. The method of claim 3 , wherein said non-rabbit nucleic acid molecules are human nucleic acid molecules.

9. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a non-rabbit Bcl-6 or a functional part or a functional derivative thereof, and

at least one rabbit anti-apoptotic nucleic acid molecule.

10. The method of claim 1 , wherein said rabbit B cell is provided with:

a nucleic acid molecule encoding a rabbit Bcl-6 or a functional part or a functional derivative thereof, and

at least one non-rabbit anti-apoptotic nucleic acid molecule.

11. The method of claim 1 , wherein said at least one anti-apoptotic nucleic acid molecule comprises a gene of the Bcl2 family.

12. The method of claim 1 , wherein said at least one anti-apoptotic nucleic acid molecule comprises a gene of the Bcl2 family selected from the group consisting of Bcl-xL, Mcl-1, Bcl-2, A1, Bcl-w, Bcl2L10, and rabbit homologues thereof and functional parts thereof and functional derivatives thereof.

13. The method of claim 1 further comprising: inducing, enhancing and/or maintaining expression of Blimp-1, or a rabbit homologue thereof, in said rabbit B cell.

14. The method of claim 1 , further comprising providing said rabbit B cell with IL21 and CD40L.

15. The method of claim 14 , wherein said IL21 is mouse or human IL21 and/or wherein said CD40L is mouse or human CD40L.

16. The method of claim 1 , comprising:

providing said rabbit B cell with a compound capable of directly or indirectly enhancing expression of Bcl-6, or expression of a rabbit homologue thereof; and/or

culturing said rabbit B cell in the presence of a compound capable of directly or indirectly enhancing expression of Bcl-6, or expression of a rabbit homologue thereof.

17. The method of claim 1 , comprising:

providing said rabbit B cell with at least one compound capable of directly or indirectly enhancing expression of Bcl-XL and/or Mcl-1 and/or Bcl-2 and/or A1 and/or Bcl-w and/or Bcl2L10 and/or or a rabbit homologue thereof; and/or

culturing said rabbit B cell in the presence of at least one compound capable of directly or indirectly enhancing expression of Bcl-XL and/or Mcl-1 and/or Bcl-2 and/or A1 and/or Bcl-w and/or Bcl2L10 and/or a rabbit homologue thereof.

18. The method of claim 1 , further comprising:

providing said rabbit B cell with at least one compound capable of directly or indirectly increasing expression of Blimp-1, or expression of a rabbit homologue of Blimp-1; and/or

culturing said rabbit B cell in the presence of at least one compound capable of directly or indirectly increasing expression of Blimp-1, or expression of a rabbit homologue of Blimp-1.

19. The method of claim 1 , wherein antibodies are harvested from the culture medium within 11-12 days from the start of the culturing.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: AIMM THERAPEUTICS B.V.
To: KLING BIOTHERAPEUTICS B.V.
Reel/Frame 055711/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: VAN HELDEN, PAULA MARIA WILHELMINA; KWAKKENBOS, MARK JEROEN; SPITS, HERGEN; BEAUMONT, TIM
To: AIMM THERAPEUTICS B.V.
Reel/Frame 050427/0434 →
Priority Claims (1)
EP 13199584 · Dec 24, 2013 · regional
Continuity (2)
Division 15106991
Related Publication 20200149007A1 · May 14, 2020